首页> 外文期刊>Journal of Drug Delivery and Therapeutics >The Benefit and Safety of Vitamin B Combination to Reduce Fatigue and Improve Quality of Life in Chronic Kidney Disease Patients
【24h】

The Benefit and Safety of Vitamin B Combination to Reduce Fatigue and Improve Quality of Life in Chronic Kidney Disease Patients

机译:维生素B组合的益处和安全性,降低慢性肾病患者的疲劳和提高生活质量

获取原文
           

摘要

Background: Chronic kidney disease (CKD) patients often have a chronic fatigue and lower QoL, thus may increase morbidity and mortality in CKD patients. Objective: The objective was to identify the benefit and safety of administration of intravenous vitamin B combination to reducing fatigue, measure the prevalence of fatigue and QoL in CKD patients. Method: This study was an observational non control study for 4 weeks in CKD patients with routine hemodyalisis 2 times/week. Every subject has a routine administration of intravenous vitamin B combination, consist of 100 mg vitamin Bsub1/sub, 100 mg vitamin Bsub6/sub, and 5000 mcg vitamin Bsub12/sub, after each hemodyalisis. Visual analogue scale (VAS) used to measure the degree of fatigue. QoL measured using SF-8 questionnaire, consist of total, physical (PCS), and mental component (MCS). Results: The prevalence of fatigue is high. The mean VAS score was 3.4±2.1 at baseline and there were 46.7% subjects with VAS score above the mean VAS score. After 4 weeks administration of vitamin B combination intravenously, the mean VAS score was decreasing from 3.4 to 2.7. The prevalence of fatigue was decreasing from 46.7% to 41%. This shifting was statistically significant (p:0.008). There was a score reduction in total component (20.19±4.8 to 19.29±4.9), PCS (13.44±3.1 to 12.99±3.5), and MCS (6.75±2.1 to 6.31±1.9). This score reduction indicated a better QoL. However, the reduction was not statistically significant. Conclusion: The prevalence of fatigue is high. Intravenous vitamin B combination considered to be effective and safe to reducing the degree of fatigue in CKD patients.
机译:背景:慢性肾病(CKD)患者往往具有慢性疲劳和低株,因此可能会增加CKD患者的发病率和死亡率。目的:目的是确定静脉内维生素B组合减少疲劳的益处和安全性,衡量CKD患者疲劳和QOL的患病率。方法:本研究是在CKD患者4周内的观察性非对照研究,常规血流性患者2次/周。每个受试者都有常规施用静脉内维生素B组合,包括100mg维生素B 1 ,100毫克维生素B 6 ,5000 mcg维生素B 12 < /亚>,在每个血流性后。用于测量疲劳度的视觉模拟量表(VAS)。使用SF-8问卷测量的QOL,由总,物理(PC)和心理组件(MCS)组成。结果:疲劳的患病率高。基线的平均VAS得分为3.4±2.1,并且有46.7%的受试者,VAS得分高于平均VAS得分。 4周静脉内施用维生素B组合后,平均VAS得分从3.4升至2.7。疲劳的患病率从46.7%降至41%。这种移位在统计学上显着(P:0.008)。总成分(20.19±4.8至19.29±4.9),PC(13.44±3.1至12.99±3.5)和MCS(6.75±2.1至6.31±1.9)。这个得分减少了一个更好的QoL。但是,减少并不统计学意义。结论:疲劳患病率高。静脉内维生素B组合被认为是有效和安全的降低CKD患者疲劳程度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号